Market Overview

UPDATE: Credit Suisse Initiates Pharmacyclics at Outperform on Pure Play Potential

Related PCYC
Pharmacyclics Reports IMRUVICA Data Shows Safety, Durability of Response at Two-Year Follow-Up in Mantle Cell Lymphoma
AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate Imbruvica In Hematologic Cancers

Credit Suisse initiated coverage on Pharmacyclics, Inc. (NASDAQ: PCYC) with an Outperform rating and a $79.00 price target.

Credit Suisse noted, "We believe that PCYC is the most derisked and investible pure play in the emerging oral lymphoma/leukemia drug class with blockbuster potential. The biggest remaining question is how large the could market be. We believe that experience with Revlimid and Gleevec provide strong evidence that worldwide markets likely exceed $5B, and ibrutinib is positioned to be both first-in-class and best-in-class in key market segments."

Pharmacyclics closed at $65.15 on Monday.

Latest Ratings for PCYC

DateFirmActionFromTo
Nov 2014Morgan StanleyMaintainsEqual-weight
Nov 2014JMP SecuritiesMaintainsMarket Outperform
Nov 2014NomuraMaintainsBuy

View More Analyst Ratings for PCYC
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (PCYC)

Around the Web, We're Loving...

Get Benzinga's Newsletters